8-K: Adaptive Biotechnologies Reports Strong Q2 2025 Results

Adaptive Biotechnologies reported robust second quarter 2025 financial results, achieving profitability in its MRD business and raising full-year revenue guidance.

Summary

• Revenue for the second quarter of 2025 was $58.9 million, representing a 36% increase from the second quarter in the prior year.
• The Minimal Residual Disease (MRD) business, which contributed 85% of total revenue, grew 42% year-over-year to $49.9 million.
• The MRD business achieved profitability in the second quarter of 2025 with Adjusted EBITDA of $1.9 million.
• clonoSEQ test volume in the second quarter of 2025 grew 37% to 25,321 tests delivered versus the second quarter of 2024.
• Net loss for the second quarter of 2025 was $25.6 million, a significant improvement from a net loss of $46.2 million for the same period in 2024.
• Adjusted EBITDA (non-GAAP) was a loss of $7.2 million for the second quarter of 2025, compared to a loss of $21.4 million for the second quarter of the prior year.
• Full year 2025 MRD revenue guidance was raised to a new range of $190 million to $200 million, implying annual growth of 31% to 37%.
• Total company full year 2025 cash burn guidance was reduced to a new range of $45 million to $55 million.
• Cash, cash equivalents, and marketable securities totaled $222.0 million as of June 30, 2025.

Sentiment

Score: 8

Explanation: The company reported strong financial performance, particularly in its core MRD business, achieving profitability in that segment and significantly reducing overall net loss. Raised revenue guidance and lowered cash burn guidance indicate positive momentum and improved financial discipline. While still operating at a net loss, the trajectory is clearly positive.

Positives

• Total revenue increased 36% year-over-year to $58.9 million.
• MRD business revenue grew 42% year-over-year to $49.9 million, demonstrating strong segment performance.
• MRD business achieved profitability with Adjusted EBITDA of $1.9 million in Q2 2025, a key financial milestone.
• clonoSEQ test volume increased 37% year-over-year to 25,321 tests, indicating strong product adoption.
• Net loss significantly reduced by 44.6% to $25.6 million from $46.2 million in the prior year, showing improved financial efficiency.
• Adjusted EBITDA improved by 66.4% to a loss of $7.2 million from a loss of $21.4 million in the prior year.
• Full year 2025 MRD revenue guidance was raised to $190 million $200 million (from $180 million $190 million), reflecting increased confidence in future performance.
• Full year 2025 total company cash burn guidance was reduced to $45 million $55 million (from $50 million $60 million), indicating better cash management.
• Recognized $5.5 million in MRD pharma regulatory milestone revenue, highlighting successful partnership achievements.
• Launched integration of clonoSEQ into Flatirons OncoEMR, expanding market reach and accessibility.
• Implemented NovaSeq X Plus for clonoSEQ clinical sequencing, enhancing diagnostic capabilities.

Negatives

• The company still reported a net loss of $25.6 million for the quarter.
• Total company Adjusted EBITDA remains a loss of $7.2 million, indicating overall unprofitability.
• Interest expense from the revenue interest purchase agreement increased to $2.9 million from $2.7 million in the prior year.
• Cash, cash equivalents and marketable securities decreased to $222.0 million as of June 30, 2025, from $283.752 million in total current assets as of December 31, 2024.

Risks

• Ability to develop, commercialize, and achieve market acceptance of current and planned products and services.
• Uncertainties related to research and development efforts.
• Risks associated with business strategies, use of capital, results of operations, financial position, and future operational plans.
• Actual results may materially differ from forward-looking statements due to various factors described in SEC filings.
• Forward-looking statements are based on a combination of facts and future projections, which may not prove accurate.

Future Outlook

Adaptive Biotechnologies raised its full year 2025 MRD revenue guidance to a new range of $190 million to $200 million, implying annual growth of 31% to 37%. The company also reduced its total company full year 2025 cash burn guidance to a new range of $45 million to $55 million. Full year total company operating expenses, including cost of revenue, are expected to be between $335 million and $345 million.

Management Comments

• "We delivered an outstanding second quarter, achieving profitability in our MRD business with accelerating topand bottom-line growth." Chad Robins, Chief Executive Officer and Co-founder.
• "With 42% MRD revenue growth, 37% clonoSEQ volume growth and positive MRD adjusted EBITDA, we’re raising our MRD revenue guidance and lowering total company cash burn targets." Chad Robins, Chief Executive Officer and Co-founder.
• "We’re executing with discipline, urgency and precision to drive impact in MRD, advance Immune Medicine and create lasting value for patients, partners and shareholders." Chad Robins, Chief Executive Officer and Co-founder.

Industry Context

The company's focus on translating adaptive immune system genetics into clinical products, particularly in Minimal Residual Disease (MRD) and Immune Medicine, aligns with the growing trend of precision medicine and personalized diagnostics in biotechnology. The integration of clonoSEQ into Flatirons OncoEMR suggests a strategic move towards broader adoption within community oncology, reflecting the industry's push for more integrated and accessible diagnostic tools in cancer care. The implementation of NovaSeq X Plus indicates adoption of advanced sequencing technologies to enhance diagnostic capabilities, keeping pace with technological advancements in the genomics sector.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, improved profitability in the MRD segment, reduced net loss, and raised financial guidance, suggesting a stronger financial outlook and potential for increased shareholder value.
• Patients: Positive impact through the continued development and commercialization of immune-driven clinical products like clonoSEQ, and its integration into electronic medical record platforms, potentially improving diagnosis and treatment of diseases like cancer.
• Partners: Positive impact through successful collaborations, evidenced by the $5.5 million MRD pharma regulatory milestone revenue, indicating successful progress in drug development partnerships.
• Employees: Positive impact from a growing and improving financial position, which can lead to greater job security and potential for growth opportunities.

Next Steps

• Management will host a conference call to discuss its second quarter 2025 financial results on Tuesday, August 5, 2025, at 4:30 PM Eastern Time.

Key Dates

Recommendation

The company demonstrated strong operational execution in Q2 2025, highlighted by 42% MRD revenue growth and the achievement of profitability in this key segment. The significant reduction in net loss and improved Adjusted EBITDA, coupled with raised full-year MRD revenue guidance and reduced cash burn targets, signal a positive financial trajectory. Strategic advancements like clonoSEQ integration into Flatirons OncoEMR and NovaSeq X Plus implementation enhance market penetration and operational efficiency. These factors suggest a strong underlying business momentum and improved financial health, making it an attractive investment opportunity.

Keywords

Biotechnology, Minimal Residual Disease, MRD, clonoSEQ, Immune Medicine, Financial Results, Q2 2025, ADPT, Oncology, Diagnostics, SEC Filing, Adaptive Immune System